

Special Issue

Kidney Disease: From Basic Research to Clinical Practice

Message from the Guest Editor

Chronic kidney disease (CKD), with a reported global prevalence of 11–13%, is a great challenge for health systems due to its economic and social implications. As it is a chronic and irreversible disease, treatment is aimed at slowing its progression. Serum creatinine quantification is the method of choice for diagnosis and classification; however, this test has limited clinical sensitivity, which has led to the search for new markers for timely diagnosis and monitoring. From this perspective, the use of metabolomics and animal models has allowed the identification and study of new metabolites, which are future biomarker candidates in clinical practice. The objective of this Special Issue is to collect articles that analyze the metabolomic profile of CKD, both in experimental and in vivo models. Those currently being investigated and new candidate markers are used to further improve the determination of kidney function. All studies that analyze markers in CKD are welcome, including clinical trials on metabolomics, as well as studies on genetics, biochemical markers in polycystic kidney disease and novel therapeutic approaches.

Guest Editor

Dr. Rafael Fernández Castillo

Faculty of Health Sciences, University of Granada, 18071 Granada, Spain

Deadline for manuscript submissions

closed (25 June 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/183106

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).